1. The liver microsomal metabolism of [4-'4C] widely used hypolipidaemic drug that lowers the concentrations of serum cholesterol and triglycerides in man and in the rat. Its cholesterol-lowering effect is as yet not fully understood. In a previous investigation evidence was given that the 7a-hydroxylation of cholesterol, which is the rate-limiting step in bile acid formation, was not influenced by clofibrate treatment in rat liver (Einarsson et al., 1974a ).
7a-hydroxy4-[6f6-3H]cholesten-3-one, 5fi-[7fi-3H]cholestane-3a,7ja-diol and [3H]lithocholic acid was studied in control and clofibrate (ethyl p-chlorophenoxyisobutyrate)-treated rats. 2. The extent of 7oc-hydroxylation of exogenous [4-14C] cholesterol and endogenous cholesterol, the latter determined with a mass fragmentographic technique, was the same in the two groups of rats. The extent of 12a-hydroxylation of 7a-hydroxy4-cholesten-3-one and 5fi-cholestane-3j,7a-diol was increased by about 60 and 120% respectively by clofibrate treatment. The 26-hydroxylation of 5fl-cholestane-3aj,7a-diol was not significantly affected by clofibrate. The 601-hydroxylation of lithocholic acid was about 80 % higher in the clofibrate-treated animals than in the controls. 3. The results are discussed in the context of present knowledge about the liver microsomal hydroxylating system and bile acid formation in patients with hypercholesterolaemia, treated with clofibrate.
Clofibrate (ethyl p-chlorophenoxyisobutyrate) is a widely used hypolipidaemic drug that lowers the concentrations of serum cholesterol and triglycerides in man and in the rat. Its cholesterol-lowering effect is as yet not fully understood. In a previous investigation evidence was given that the 7a-hydroxylation of cholesterol, which is the rate-limiting step in bile acid formation, was not influenced by clofibrate treatment in rat liver (Einarsson et al., 1974a) .
In contrast Cohen et al. (1974) showed that clofibratetreated rats have a decreased faecal bile acid excretion compared with control rats. It was suggested by Cohen et al. (1974) that our results might be explained by the system for enzyme assay in vitro used for the 7a-hydroxylase. With the type of assay used, only 7a-hydroxylation of exogenous cholesterol is determined, and the possibility cannot be excluded that this conversion does not reflect changes in 7a-hydroxylation of endogenous cholesterol.
To clarify further the influence of clofibrate on the formation of bile acids, the 7a-hydroxylation of cholesterol was studied with a recently developed mass-fragmentographic technique by which the mass of 5-cholestene-3fl,7a-diol formed from endogenous cholesterol can be determined (Bjorkhem & Danielsson, 1974a) . In addition the effects of clofibrate on some other hydroxylases important in the biosynthesis and metabolism of bile acids were studied.
Materials and Methods
Radioactive steroids [4-14C] Hydroxy-4-[6fi-3H]cholesten-3-one (specific radioactivity 2.7puCi/amol) was prepared as described by Bjorkhem (1969) and 5/8-[71J-3H]cholestane-3a,7oc-diol (specific radioactivity 6.5pCi/,umol) was synthesized as described by Bjorkhem & Gustafsson (1973). [3H]Lithocholic acid (specific radioactivity 4,Ci/,umol) was from New England Nuclear Corp., Boston, MA, U.S.A. NADP+, glucose 6-phosphate and glucose 6-phosphate dehydrogenase were from SigmaChemical Co., St. Louis, MO, U.S.A. Clofibrate (Atromidin) was from Scanmeda, Goteborg, Sweden.
Animals andpreparation ofhomogenates
Adult male rats of the Sprague-Dawley strain weighing approx. 200g were used. They were divided into two groups of six animals and were fed on crushed rat diet pellets (R3; Astra-Ewos AB, S6dertalje, Sweden) for 1 month ad lib. For one of the groups the food was supplemented with 0.3 % clofibrate. The drug was dissolved in aq. 95 % (v/v) ethanol, which was added to the crushed pellets and left to evaporate at room temperature (20°C). At this dose the drug is reported to have a maximum effect on the plasma cholesterol concentration without producing toxic manifestations (Thorp & Waring, 1962) .
After overnight starvation, the rats were killed with a blow on the neck. The livers were excised, immediately chilled on ice, blotted, weighed and minced into small pieces. A 20% (w/v) homogenate was prepared in 0.3M-sucrose containing 75mM-nicotinamide, 2m1-EDTA and 20m 2-mercaptoethanol, by usig a Potter-Elvehijem homogenizer equipped with a loosely fitting pestle. The homognate was centrifuged at 20000g for 15min. The microsomal fraction was isolated by centrifiging the 20000g supernatant for 1 h at 100000g, and washed once in the homogenizing medium by resuspension and re-centrifugation at lOOOOOg for 30min. A part of the microsomal fraction, intended for assay of cholesterol 7a-hydroxylase activity, was suspended in 0.1 Mpotassium phosphate buffer, pH 7.0, containing 28mM-nicotinamide. The remaiing part of the microsomal fraction was suspended in a modified Bucher medium (Bergstrom & Gloor, 1955 (Bj6rkhem & Danjelsson, 1975) . The incubation was for 15mn at 370C and was terminated by the addition of 20vol. of chloroform/methanol (2:1, v/v). Just before addition of chloroform/methanol to the incubation mixture, 2H-labeIled 5-cholestene-3f,7ta-diol (3ug) was added as internal standard. The chloroform phase was analysed by t.l.c. (Bjorkhem & Danielsson, 1975 plate. The mass of 5-cholestene-3,f,7a-diol formed from endogenous cholesterol was determined by means ofcombined gas-liqud chromatography-mass spectrometry of the appropriate chromatograplic fraction by using an LKB instrument equipped with a 1.5% SE-30 column (Bjorkhem & Danielsson, 1974a .
To 4ml of liver microsomal fraction, supplemented with an NADPH-generating system, 7a-hydroxy-4-[6,B-3H]cholesten-3-one (50,ug) was added. The incubation was for 12min at 370C and was terminated as described above. Further analysis was performed as reported previously (Bjorkhem & Einarsson, 1970) except that the conversion of the labelled substrate was determined by scanning the chromatoplate with a thin-layer radioscanner.
Incubations with 5flS[7,f-3H]cholestane-3a,7a-diol To a mixture of 3 ml of liver microsomal fraction and an NADPH-generating system, 5f1-[7,8-3H]-cholestane-3a,7a-diol (250pg) was added. The incubation was for 20min and -was terminated as described above. Further analysis was performed as described by Bjorkhem & Gustafsson (1973 The principal metabolite formed from 7a-hydroxy-4-cholesten-3-one in the microsomal fraction is 7a, 12 o-dihydroxyy4cholesten-3-one (Einarsson, 1968; Bj6rkhem & Einarsson, 1970) . The extent of 12a-hydroxylation was increased by about 60% in the clofibrate-treated rats compared with the control rats.
The two main metabolites formed from 5,&. cholestane-3a,7a-diol in the microsomal fraction of rat liver are 5fi.cholestane-3a,7a,12a-triol and 5,l-cholestane-3a,7a,26-triol (Bjorkhem & Gustafsson, 1973 ). The extent of12a-hydroxylation was more than twice as great in clofibrate-treated rats as in control animals. Also the 26-hydroxylase activity tended to increase on clofibrate treatment, but no significant difference was obtained.
Lithocholic acd has previously been shown to be mainly 6f6-hydroxylated in the microsomal fraction (Einarsson & Johansson, 1969) . The extent of 6fi-hydroxylation was increased by about 80% by clofibrate treatnent.
Discussion
The main bile acids formed from cholesterol in rat liver as well as in human liver are cholic acid (3ca,7,22a-trihydroxy-5,f-cholanoic acid) and chenodeoxycholic acid (3a,7a-dihydroxy-5fi-cholanoic acid) (for a review see Danielsson, 1973) . During intestinal passage both cholic acid and chenodeoxycholic acid are partly 7a-dehydroxylated to yield deoxycholic acid (3ra,12a-dihydroxy-5fl-choJanoic acid) and lithocholic acid (3a-hydroxy-5,B-cholanoic acid) respectively. In rat liver reabsorbed deoxycholic acid is rehydroxylated in the 12a-position and lithocholic acid is 6fi-hydroxylated. Chenodeoxycholic acid is also further hydroxylated in the 6,6-position.
The 6fi-hydroxylase active on chenodeoxycholic acid has similar properties to the lithocholic acid 6,8-hydroxylase. Human liver has a very low ability to hydroxylate bile acids (Bjbrkhem et al., 1973a) .
The first and rate-limiting step in the degradation of cholesterol into bile acids is 7a-hydroxylation (for a review see Danielsson, 1973) . Subsequent oxidation yields 7a-hydroxy-4-cholesten-3-one. This compound Vol. 156 is considered to be a key intermediate and might be further 12a-hydroxylated in cholic acid biosynthesis. If not 12a-hydroxylated, 7arhydroxy4-cholesten-3-one might be converted into 5f-cholestane-3a,7zdiol in the soluble fraction ofthe cell. The latter compound might be either 12a-hydroxylated or 26-hydroxylated. With 26.hydroxylation, chenodeoxycholic acid will be the final metabolite, since introduction of a 26. hydroxyl group seems to prevent subsequent 12oc hydroxylation. At least in the rat, the ratio between cholicacidand chenodeoxycholicacid formed appears to be determined by the relative activity of the microsomal 12ac-and 26-hydroxylase (Bj3rkhem & Danielsson, 1974b; Cohen et al., 1975) . The mAin pathway for bile acid synthesis in human liver seems to be analogous to that in rat (Bjorkhem et al., 1968 (Bjorkhem et al., , 1975 . The possibility has been discussd, however, that side-chain oxidation starts with a 25-hydroxylation instead of a 26-hydroxylation in biosynthesis of bile acids in the human liver (Setoguchi eta!., 1974) .
Earlier works have shown that clofibrate increases liverweight (Best & Duncan, 1964) , induces proliferation of smooth-surfaced endoplasmic reticulum in rat liver cells (Hess et al., 1965) and increases the content of cytochrome P4SO in rat liver microsomal fraction (Salvador et aL, 1970; Lewis et al., 1974) . Clofibrate influences hepatic drug metabolism in rats (Lewis et al., 1974) and alters the metabolism of several steroid hormones, e.g. testosterone (Salvador etal., 1970) ,androstenedione (Einarsson etal., 1974a) , progesterone and oestradiol (Einarsson eta!., 1973a Bj6rkhem & Danielsson, 1974b (Johansson, 1970) and by hypothyroidism (Mitropoulos et al., 1968 (Bernhardsson et al., 1973) . It is also possible that clofibrate induces the specific type of cytochrome P-450 activity involved in 12a-hydroxylation. The finding that 7a-hydroxylation of cholesterol was uninfluenced by clofibrate treatment is in accordance with an earlier study (Einarsson et al., 1974a) . Cohen et al. (1974) reported that clofibrate-treated rats have about 25 % lower faecal excretion of bile acids compared with controls. Whether the relatively small discrepancy between our results in vitro and those of Cohen et al. (1974) in vivo depend on the different experimental conditions or on differences in the species of rats is difficult to assess.
The finding that the 12a-hydroxylase, in contrast with the 7a-hydroxylase and the 26-hydroxylase, was stimulated by clofibrate treatment may have some bearing on recent observations in patients with hyperlipoproteinaemia type II (hypercholesterolaemia). These patients have a low ratio between cholic acid and chenodeoxycholic acid synthesis, depending on a subnormal formation of cholic acid (Einarsson et al., 1974b) . During treatment with clofibrate the combined synthesis of cholic acid and chenodeoxycholic acid was unchanged, but the ratio between cholic acid and chenodeoxycholic acid increased in five out ofsix patients (Einarsson eta., 1973b) .
